China's Commercial Health Insurance Formulary Development: Current State and Future Directions
Executive Summary
The commercial health insurance sector in China presents substantial opportunities for growth, with the development of commercial insurance
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions
During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
Policy Push for Long-Term Huiminbao: The Impact on Innovative Medicine
In early January, the National Administration of Financial Regulation (NAFR) issued a draft titled "Notice on Promoting the Smooth
Closing the Affordability Gap: Can China’s Commercial Health Insurance Deliver?
At the end of 2021, individual out-of-pocket (OOP) spending in China constituted 27.7% of total healthcare expenditure (THE), soaring
Access Pathway for Innovative Medicines in China: City Commercial Health Insurance ("Huiminbao")
In the first installment of this 3-part China access pathway series, we discussed the basic social medical insurance (BMI)/the
